Long-term use of liposomal nebulized amikacin and tedizolid for the treatment of disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation.
Amikacin
/ pharmacology
Anti-Bacterial Agents
/ therapeutic use
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunosuppressive Agents
/ adverse effects
Liposomes
/ administration & dosage
Male
Middle Aged
Nebulizers and Vaporizers
Nocardia
/ drug effects
Nocardia Infections
/ diagnosis
Oxazolidinones
/ pharmacology
Tetrazoles
/ pharmacology
Time Factors
Allogeneic hematopoietic stem cell transplantation
Liposomal nebulized amikacin
Nocardiosis
Tedizolid
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
21
11
2020
accepted:
04
02
2021
pubmed:
12
3
2021
medline:
27
11
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Nocardiosis is a life-threatening opportunistic infection in immunocompromised patients. Herein, we present successful adjunctive use of liposomal nebulized amikacin and tedizolid in a recipient of allogeneic hematopoietic stem cell transplantation infected with Nocardia nova complex who presented multiple complications to conventional therapeutic options.
Identifiants
pubmed: 33694036
doi: 10.1007/s10096-021-04186-6
pii: 10.1007/s10096-021-04186-6
doi:
Substances chimiques
Anti-Bacterial Agents
0
Immunosuppressive Agents
0
Liposomes
0
Oxazolidinones
0
Tetrazoles
0
Amikacin
84319SGC3C
tedizolid
97HLQ82NGL
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2033-2036Investigateurs
F Ader
(F)
V Alcazer
(V)
E Bachy
(E)
M Balsat
(M)
F Barraco
(F)
M Boccard
(M)
A Conrad
(A)
S Ducastelle-Leprêtre
(S)
O Dumitrescu
(O)
D Dupont
(D)
V Escuret
(V)
E Ferrant
(E)
T Ferry
(T)
E Frobert
(E)
H Ghesquières
(H)
L Karlin
(L)
H Labussière-Wallet
(H)
M-V Larcher
(MV)
F Laurent
(F)
B Lina
(B)
G Lina
(G)
J Menotti
(J)
P Miailhes
(P)
G Monneret
(G)
F Morfin-Sherpa
(F)
T Perpoint
(T)
M Rabodonirina
(M)
M Renault
(M)
C Roure-Sobas
(C)
V Safar
(V)
G Salles
(G)
P Sesques
(P)
X Thomas
(X)
F Valour
(F)
F Venet
(F)
F Wallet
(F)
M Wallon
(M)
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Couble A, Rodríguez-Nava V, de Montclos MP, Boiron P, Laurent F (2005) Direct detection of Nocardia spp. in clinical samples by a rapid molecular method. J Clin Microbiol 43(4):1921–1924. https://doi.org/10.1128/JCM.43.4.1921-1924.2005
doi: 10.1128/JCM.43.4.1921-1924.2005
pubmed: 15815019
pmcid: 1081390
Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T (1993) Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 31(2):175–178. https://doi.org/10.1128/JCM.31.2.175-178.1993
doi: 10.1128/JCM.31.2.175-178.1993
pubmed: 8381805
pmcid: 262730
Clinical and Laboratory Standards Institute (2011) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard. Document M24-A. CLSI, Wayne, PA
Lebeaux D, Morelon E, Suarez F, Lanternier F, Scemla A, Frange P, Mainardi J-L, Lecuit M, Lortholary O (2014) Nocardiosis in transplant recipients. Eur J Clin Microbiol Infect Dis 33(5):689–702. https://doi.org/10.1007/s10096-013-2015-5
doi: 10.1007/s10096-013-2015-5
pubmed: 24272063
McTaggart LR, Doucet J, Witkowska M, Richardson SE (2015) Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother 59(1):269–275. https://doi.org/10.1128/AAC.02770-14
doi: 10.1128/AAC.02770-14
pubmed: 25348540
Ye X, Huang A, Wang X, Wen C, Hu L, Lin G (2018) Linezolid inhibited synthesis of ATP in mitochondria: based on GC-MS metabolomics and HPLC method. Biomed Res Int 2018:3128270. https://doi.org/10.1155/2018/3128270
doi: 10.1155/2018/3128270
pubmed: 30410924
pmcid: 6206563
Quon BS, Goss CH, Ramsey BW (2014) Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 11(3):425–434. https://doi.org/10.1513/AnnalsATS.201311-395FR
doi: 10.1513/AnnalsATS.201311-395FR
pubmed: 24673698
pmcid: 4028738
Brain JD, Valberg PA (1979) Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 120(6):1325–1373. https://doi.org/10.1164/arrd.1979.120.6.1325
doi: 10.1164/arrd.1979.120.6.1325
pubmed: 391112
Mifuji Lira RM, Flores AYL, Carmona MCS, Stern AO (2016) Experimental granulomatous pulmonary nocardiosis in BALB/C Mice. PLoS One 11(6):e0157475. https://doi.org/10.1371/journal.pone.0157475
doi: 10.1371/journal.pone.0157475
pubmed: 27303806
pmcid: 4909231
Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, Nashed M, Joseph J, Perkins WR, DiPetrillo K (2018) Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol 9:915. https://doi.org/10.3389/fmicb.2018.00915
doi: 10.3389/fmicb.2018.00915
pubmed: 29867826
pmcid: 5964161
Brown-Elliott BA, Wallace RJ (2017) In vitro susceptibility testing of tedizolid against isolates of Nocardia. Antimicrob Agents Chemother 61(12):e01537–e01517. https://doi.org/10.1128/AAC.01537-17
doi: 10.1128/AAC.01537-17
pubmed: 28923878
pmcid: 5700301
Nigo M, Luce AM, Arias CA (2018) Long-term use of tedizolid as suppressive therapy for recurrent methicillin-resistant Staphylococcus aureus graft infection. Clin Infect Dis 66(12):1975–1976. https://doi.org/10.1093/cid/ciy041
doi: 10.1093/cid/ciy041
pubmed: 29370350
pmcid: 6248592
Yuste JR, Serrano-Alonso M, Carmona-Torre F, Del Pozo JL, Herrero JI (2019) Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis. J Antimicrob Chemother 74(9):2817–2819. https://doi.org/10.1093/jac/dkz216
doi: 10.1093/jac/dkz216
pubmed: 31106345
Kim T, Wills AB, Markus B, Prevots DR, Olivier KN. Safety and tolerability of long term use of tedizolid for treatment of nontuberculous mycobacterial infections, poster 577. ID Week, New Orleans, LA, 26 to 30 October 2016